Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25284095 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2KDM4EPKMHRH3L3MBTL1 | |
| SCHEMBL25221067 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EHRH3L3MBTL1KMT2A | |
| SCHEMBL25293272 | 0.92 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EHRH3L3MBTL1KMT2A | |
| SCHEMBL25267557 | 0.83 | USP2 (0.35) | SMN1; SMN2 | |
| SCHEMBL25267556 | 0.83 | USP2 (0.35) | SMN1; SMN2 | |
| SCHEMBL28108703 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2KMT2ABTK | |
| SCHEMBL25258556 | 0.79 | DRD2 (0.44) | SMN1; SMN2KDM4EPKMKMT2AMEN1 | |
| SCHEMBL25290598 | 0.79 | DRD2 (0.44) | SMN1; SMN2KDM4EPKMKMT2AMEN1 | |
| SCHEMBL25762540 | 0.79 | HTT (0.47) | SMN1; SMN2 | |
| SCHEMBL25242973 | 0.79 | SMN1; SMN2 (0.39) | SMN1; SMN2HRH3L3MBTL1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203071-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | SMN1; SMN2 3008/4885KDM4E 2317/4885PKM 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.